Exact Mass: 447.34607400000004

Exact Mass Matches: 447.34607400000004

Found 81 metabolites which its exact mass value is equals to given mass value 447.34607400000004, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N-Stearoyl tyrosine

(2S)-2-[(1-hydroxyoctadecylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

C27H45NO4 (447.33484100000004)


N-stearoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoylcarnitine

3-(icosa-8,11,14,17-tetraenoyloxy)-4-(trimethylazaniumyl)butanoate

C27H45NO4 (447.33484100000004)


(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Esculeogenin A

5-(hydroxymethyl)-7,9,13-trimethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2-piperidine]-3,16-diol

C27H45NO4 (447.33484100000004)


   

N-[2,6-Di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide

N-[2,6-bis(propan-2-yl)phenyl]-2-(tetradecylsulfanyl)acetamide

C28H49NOS (447.35346640000006)


   
   
   
   

antibiotic TKR459

antibiotic TKR459

C23H45NO7 (447.319586)


   

(1alpha,7beta,14alpha,16beta)-20-ethyl-1,8,16-trimethoxy-4-methylaconitan-14-yl acetate|14-acetoxy-8-O-methylsachaconitine

(1alpha,7beta,14alpha,16beta)-20-ethyl-1,8,16-trimethoxy-4-methylaconitan-14-yl acetate|14-acetoxy-8-O-methylsachaconitine

C26H41NO5 (447.29845760000006)


   
   

N-(3alpha-Hydroxy-7-oxo-5beta-cholanoyl-(24))-glycin|nutriaglycocholic acid|Nutriaglykocholsaeure

N-(3alpha-Hydroxy-7-oxo-5beta-cholanoyl-(24))-glycin|nutriaglycocholic acid|Nutriaglykocholsaeure

C26H41NO5 (447.29845760000006)


   
   

verticinone

verticinone

C27H45NO4 (447.33484100000004)


Origin: Plant; SubCategory_DNP: Steroidal alkaloids, Veratrum alkaloids

   

Arachidonoyl-carnitine; AIF; CE0; CorrDec

Arachidonoyl-carnitine; AIF; CE0; CorrDec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; AIF; CE10; CorrDec

Arachidonoyl-carnitine; AIF; CE10; CorrDec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; AIF; CE30; CorrDec

Arachidonoyl-carnitine; AIF; CE30; CorrDec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; AIF; CE0; MS2Dec

Arachidonoyl-carnitine; AIF; CE0; MS2Dec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; AIF; CE10; MS2Dec

Arachidonoyl-carnitine; AIF; CE10; MS2Dec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; AIF; CE30; MS2Dec

Arachidonoyl-carnitine; AIF; CE30; MS2Dec

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; LC-tDDA; CE10

Arachidonoyl-carnitine; LC-tDDA; CE10

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; LC-tDDA; CE20

Arachidonoyl-carnitine; LC-tDDA; CE20

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; LC-tDDA; CE40

Arachidonoyl-carnitine; LC-tDDA; CE40

C27H45NO4 (447.33484100000004)


   

Arachidonoyl-carnitine; LC-tDDA; CE30

Arachidonoyl-carnitine; LC-tDDA; CE30

C27H45NO4 (447.33484100000004)


   

N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

"N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine"

C27H45NO4 (447.33484100000004)


   

2-docosanamidoethanesulfonic acid

2-docosanamidoethanesulfonic acid

C24H49NO4S (447.3382114000001)


   
   
   
   

CAR 20:4

3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-4-(trimethylazaniumyl)butanoate

C27H45NO4 (447.33484100000004)


   

NAT 22:0

N-docosanoyl-taurine

C24H49NO4S (447.3382114000001)


   

NA 27:5;O3

N-hexadecanoyl-alpha,O-dimethyl-L-tyrosine

C27H45NO4 (447.33484100000004)


   

N-arachidonoyl-dopamine-d8

N-[2-(3,4-dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide-5,6,8,9,11,12,14,15-d8

C28H33D8NO3 (447.35884502400006)


   

ST 24:2;O4;G

N-(3beta,7beta,dihydroxycholest-5-en-24-oyl) glycine

C26H41NO5 (447.29845760000006)


   

Methyltrioctylammonium bromide

Methyltrioctylammonium bromide

C25H54BrN (447.3439384)


   

hexadecyl-(2-hydroxycyclohexyl)-dimethylazanium,bromide

hexadecyl-(2-hydroxycyclohexyl)-dimethylazanium,bromide

C24H50BrNO (447.30755500000004)


   
   

7-Oxoglycochenodeoxycholic acid

7-Oxoglycochenodeoxycholic acid

C26H41NO5 (447.29845760000006)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   
   

(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoylcarnitine

(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoylcarnitine

C27H45NO4 (447.33484100000004)


   

Esculeogenin A

Esculeogenin A

C27H45NO4 (447.33484100000004)


A sapogenin that is spirosolane substituted by hydroxy groups at positions 3, 23 and 27 (the 3beta,5alpha,22alpha,23S,25S stereoisomer).

   

(4E,6Z)-N-(5-ethyl-5-methyl-2-oxofuran-3-yl)-3-hydroxy-8-(3-nonyloxiran-2-yl)octa-4,6-dienamide

(4E,6Z)-N-(5-ethyl-5-methyl-2-oxofuran-3-yl)-3-hydroxy-8-(3-nonyloxiran-2-yl)octa-4,6-dienamide

C26H41NO5 (447.29845760000006)


   

N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

C27H45NO4 (447.33484100000004)


   

3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-4-(trimethylazaniumyl)butanoate

3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-4-(trimethylazaniumyl)butanoate

C27H45NO4 (447.33484100000004)


   
   

(11Z,14Z,17Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]icosa-11,14,17-trienamide

(11Z,14Z,17Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]icosa-11,14,17-trienamide

C28H49NO3 (447.3712244000001)


   

(8Z,11Z,14Z,17Z)-N-(1,3-dihydroxyoctan-2-yl)icosa-8,11,14,17-tetraenamide

(8Z,11Z,14Z,17Z)-N-(1,3-dihydroxyoctan-2-yl)icosa-8,11,14,17-tetraenamide

C28H49NO3 (447.3712244000001)


   

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxydodecan-2-yl)hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxydodecan-2-yl)hexadeca-4,7,10,13-tetraenamide

C28H49NO3 (447.3712244000001)


   

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]octadeca-9,12,15-trienamide

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]octadeca-9,12,15-trienamide

C28H49NO3 (447.3712244000001)


   

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxydecan-2-yl)octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxydecan-2-yl)octadeca-6,9,12,15-tetraenamide

C28H49NO3 (447.3712244000001)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tridec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tridec-9-enamide

C28H49NO3 (447.3712244000001)


   

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexadeca-9,12-dienamide

C28H49NO3 (447.3712244000001)


   

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]hexadeca-7,10,13-trienamide

C28H49NO3 (447.3712244000001)


   

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]decane-1-sulfonic acid

C23H45NO5S (447.30182800000006)


   

(E)-3-hydroxy-2-(undecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(undecanoylamino)dodec-4-ene-1-sulfonic acid

C23H45NO5S (447.30182800000006)


   

(E)-2-(dodecanoylamino)-3-hydroxyundec-4-ene-1-sulfonic acid

(E)-2-(dodecanoylamino)-3-hydroxyundec-4-ene-1-sulfonic acid

C23H45NO5S (447.30182800000006)


   

(E)-2-(decanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid

(E)-2-(decanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid

C23H45NO5S (447.30182800000006)


   

(E)-3-hydroxy-2-(tridecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tridecanoylamino)dec-4-ene-1-sulfonic acid

C23H45NO5S (447.30182800000006)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]tetradec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]tetradec-9-enamide

C28H49NO3 (447.3712244000001)


   

cis-5-(6-Formylhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

cis-5-(6-Formylhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

C30H41NO2 (447.31371260000003)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tridec-8-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tridec-8-enamide

C28H49NO3 (447.3712244000001)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]dodec-5-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]dodec-5-enamide

C28H49NO3 (447.3712244000001)


   

(10S)-10,20-dihydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-17-one;hydrate

(10S)-10,20-dihydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-17-one;hydrate

C27H45NO4 (447.33484100000004)


   

O-arachidonoylcarnitine

O-arachidonoylcarnitine

C27H45NO4 (447.33484100000004)


An O-acylcarnitine having arachidonoyl as the acyl substituent.

   

N-docosanoyltaurine

N-docosanoyltaurine

C24H49NO4S (447.3382114000001)


A fatty acid-taurine conjugate derived from docosanoic acid.

   

SPHP(23:2)

SPHP(d23:2)

C23H46NO5P (447.31134360000004)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   
   

(1s,12s,15r,16s,17s,20s)-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

(1s,12s,15r,16s,17s,20s)-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

C30H41NO2 (447.31371260000003)


   

(1r,2r,3ar,3br,5as,7s,9ar,9br,11as)-2,7-dihydroxy-1-[(1s)-1-[(2s,3r,5s)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-6-one

(1r,2r,3ar,3br,5as,7s,9ar,9br,11as)-2,7-dihydroxy-1-[(1s)-1-[(2s,3r,5s)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-6-one

C27H45NO4 (447.33484100000004)


   

(1s,2r,5s,7s,10s,11s,14s,15r,16s,17s,20s,22r,24s)-20-(hydroxymethyl)-10,14,16-trimethyl-23-oxa-18-azahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²⁴.0¹⁷,²²]pentacosane-7,22-diol

(1s,2r,5s,7s,10s,11s,14s,15r,16s,17s,20s,22r,24s)-20-(hydroxymethyl)-10,14,16-trimethyl-23-oxa-18-azahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²⁴.0¹⁷,²²]pentacosane-7,22-diol

C27H45NO4 (447.33484100000004)


   

2-[(1-hydroxyhexadecylidene)amino]-3-(4-methoxyphenyl)-2-methylpropanoic acid

2-[(1-hydroxyhexadecylidene)amino]-3-(4-methoxyphenyl)-2-methylpropanoic acid

C27H45NO4 (447.33484100000004)